China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen

BEIJING - Shanghai-headquartered Hutchison MediPharma has frozen development of a cancer drug after Phase II clinical trials conducted in China produced inconclusive data on the efficacy of the medicine, according to company executives